Table 4.

Association Between Endothelial Repair and Clinical Markers for Hantaviral Disease Outcome^a

	SDF-1 (pg/mL)	EPO (mIU/mL)	Ang-2 (pg/mL)	VEGF (pg/mL)
Clinical laboratory values
Thrombocytes, 109/L	β= −0.971 P = .026	β= -1.314 P = .012	β= −0.053 P = .004	β= 0.228 P = .136
Creatinine, μmol/L	β= 0.426 P = .31	β= −0.525 P = .052	β= 0.03 P = .167	β= 0.32 P = .319
Albumin, g/L	β= −0.027 P = .015	β= −0.218 P = .017	β= −0.001 P < .001	β= −0.007 P = .02
Blood pressure
Systolic, mmHg	β= −0.148 P = .096	β= −0.074 P = .042	β= −0.008 P < .001	β= 0.011 P = .718
Diastolic, mmHg	β= −0.032 P = .391	β= 0.013 P = .592	β= −0.001 P = .407	β= −0.012 P = .466
Hypoxia
IGFBP-1	β= 96.009 P = .016	β= 257.36 P = .000	β= 4.968 P = .050	β = 16.039 P = .35
Disease severityb	ρ = 0.454 P = .089	ρ = 0.031 P = .899	ρ = 0.344 P = .149	ρ = −0.063 P = .799

Abbreviations: Ang-2, angiopoietin; EPO, erythropoietin; IGFBP-1, insulin-like growth factor binding protein 1; SDF-1, stromal cell-derived factor 1; VEGF, vascular endothelial growth factor.

^a The estimated β-coefficients from the generalized estimating equations analysis is given along with the P value. This result corresponds to the change in endothelial activation marker levels for 1 unit increase for continuous covariates (slope). Significant associations are shown highlighted in bold.

^b The maximal values for each marker is associated with disease severity (mild vs moderate/severe disease groups) using Spearman's rank correlation coefficient analysis.